Cost-Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients with Advanced ALK Positive Non-Small Cell Lung Cancer in a Publicly Funded System (Ontario, Canada)

✍ Scribed by Djalalov, S.; Beca, J.; Hoch, J.S.; Krahn, M.D.; Tsao, M.S.; Cutz, J.C.; Leighl, N.

• Book ID: 122641446
• Publisher: John Wiley and Sons
• Year: 2013
• Tongue: English
• Weight: 61 KB
• Volume: 16
• Category: Article
• ISSN: 1098-3015
• DOI: 10.1016/j.jval.2013.08.503